An observational study in Anorexia Nervosa, Avoidant / Restrictive Food Intake Disorder and Autism Spectrum Disorder, sponsored by Fondazione IRCCS San Gerardo dei Tintori. Not yet recruiting at 4 sites in Italy. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fondazione IRCCS San Gerardo dei Tintori · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Anorexia Nervosa with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Anorexia Nervosa · Italy.
Among the 31 studies in Anorexia Nervosa with a site in Italy, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2026, is one of 19 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 31st registered.
471 studies on the registry are indexed under Anorexia Nervosa; 128 are open to participants now.
Browse Anorexia Nervosa studies →11 of the 31 studies in Anorexia Nervosa with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 15–40 · Healthy volunteers
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 14–65 · Healthy volunteers
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 12–40 · Women only
Istituto Auxologico Italiano · Sites in Italy
Ages 16–65
University of Padova · Sites in Italy
Ages 14+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.
This study: 13 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 78 across 143 observational studies indexed under Anorexia Nervosa.
Median enrollment 74 across the 12 interventional studies, 60 across the 19 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS San Gerardo dei Tintori is the lead sponsor of 11 studies on the registry; 9 are open to participants now.
Fondazione IRCCS San Gerardo dei Tintori has 1 study filed under Anorexia Nervosa — fewer than ten, so there is no comparison to draw.
3 of the studies in Anorexia Nervosa with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106645University of PadovaIntermittent Theta Burst Transcranial Magnetic Stimulation of the Right Parietal Lobe in Anorexia Nervosa | 2027-01-15 |
| NCT07295470Istituto Auxologico ItalianoSleep and Activity For Eating Disorders | 2027-05 |
| NCT07946887Fondazione IRCCS San Gerardo dei TintoriInteroception in Adolescents With Restrictive Eating Disorders and Autism Spectrum Disorder | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Anorexia Nervosa with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to describe interoception (the ability to sense signals from inside the body, such as heartbeat, hunger, and fullness) in three groups of adolescents aged 13 to 18: those with restrictive eating disorders (REDs), those with autism spectrum disorder (ASD), and those with both REDs and ASD.
The main questions it aims to answer are:
In each group, researchers will also explore whether interoceptive accuracy and sensitivity are associated with:
Participants will:
All information will be collected during the standard clinical assessment, with no extra visits or procedures.
Restrictive eating disorders (REDs), including anorexia nervosa and avoidant/restrictive food intake disorder, and autism spectrum disorder (ASD) frequently co-occur, and their overlap is associated with more severe psychopathology. Interoception, the process by which the nervous system senses, interprets, and integrates signals from inside the body, has been found to be impaired in both conditions, but little is known about interoception in adolescents with REDs and comorbid ASD.
Following the multidimensional model proposed by Garfinkel et al. (2015), this multicenter prospective observational study will assess two dimensions of interoception: interoceptive accuracy (objective performance in detecting internal body signals) and interoceptive sensitivity (self-reported perception of body signals). Three clinical groups of adolescents will be described: REDs only, ASD only, and REDs with comorbid ASD.
No study-specific procedures are planned. During the standard psychodiagnostic assessment, participants complete a modified Heartbeat Counting Task (HCT) with a time estimation control task, the MAIA-2, and other self-report questionnaires (TAS-20, EDI-3, SCL-90-R, AQ, EQ, DERS-IT-SF), and undergo cognitive assessment (WISC-V). Socio-demographic and clinical data are also collected. Interoceptive accuracy and sensitivity will be described in each group with measures of location and variability and 95% confidence intervals, and their associations with socio-demographic, clinical, and psychological variables will be explored.
Adolescents aged 13 to 18 years with a confirmed DSM-5-TR diagnosis of restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder), autism spectrum disorder (level 1), or restrictive eating disorder with comorbid autism spectrum disorder (level 1), recruited during their standard psychodiagnostic assessment among patients under the care of four Italian child and adolescent neuropsychiatry centers: Fondazione IRCCS San Gerardo dei Tintori (Monza, coordinating center), IRCCS Istituto delle Scienze Neurologiche di Bologna, Azienda Ospedale-Università Padova, and Fondazione IRCCS Mondino (Pavia).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) according to DSM-5-TR criteria, without autism spectrum disorder.
Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of autism spectrum disorder, level 1, according to DSM-5-TR criteria, without a restrictive eating disorder.
Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) and comorbid autism spectrum disorder, level 1, according to DSM-5-TR criteria.
Interoceptive Accuracy Measured by the Heartbeat Counting Task (HCT)
Interoceptive accuracy assessed with a modified version of the Heartbeat Counting Task. Participants silently count their heartbeats, without taking their pulse, during four randomized time intervals while heart rate is recorded with a finger pulse oximeter. The accuracy score is calculated as the mean across intervals of \[1 - \|(recorded heartbeats - counted heartbeats) / recorded heartbeats\|\] × 100. Scores range from 0 to 100, with higher scores indicating greater interoceptive accuracy.
Time frame: At enrollment, during the standard diagnostic assessment
Interoceptive Sensibility Measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2)
Self-reported interoceptive sensibility assessed with the MAIA-2, a 37-item questionnaire rated on a 6-point scale (0-5). Mean scores are calculated for each of the 8 subscales (Noticing, Not-Distracting, Not-Worrying, Attention Regulation, Emotional Awareness, Self-Regulation, Body Listening, Trusting) and range from 0 to 5. Higher scores indicate greater interoceptive sensibility.
Time frame: At enrollment, during the standard diagnostic assessment
Correlations Between Interoceptive Measures and Sociodemographic Variables
Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with gender (number of participants per category) and age (years), collected from clinical records. Analyzed in each clinical group.
Time frame: At enrollment, during the standard diagnostic assessment
Correlations Between Interoceptive Measures and Clinical Variables
Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with body mass index (BMI, kg/m²), duration of illness (months), and Full Scale IQ measured by the WISC-V (standard score, mean 100, SD 15), collected from clinical records. Analyzed in each clinical group.
Time frame: At enrollment, during the standard diagnostic assessment
Alexithymia Measured by the Toronto Alexithymia Scale (TAS-20)
Alexithymia assessed with the TAS-20, a 20-item self-report questionnaire rated on a 5-point Likert scale. Total score ranges from 20 to 100 (subscales: Difficulty Identifying Feelings, Difficulty Describing Feelings, Externally Oriented Thinking); higher scores indicate greater alexithymia. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.
Time frame: At enrollment, during the standard diagnostic assessment
Eating Disorder Symptom Severity Measured by the Eating Disorder Inventory-3 (EDI-3)
Eating disorder symptoms assessed with the EDI-3, a 91-item self-report questionnaire comprising 12 primary scales and 6 composite scales, including the Eating Disorder Risk Composite. Raw scores are converted to T-scores; higher scores indicate greater symptom severity. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.
Time frame: At enrollment, during the standard diagnostic assessment
General Psychopathology Measured by the Symptom Checklist-90-Revised (SCL-90-R)
General psychopathology assessed with the SCL-90-R, a 90-item self-report questionnaire rated from 0 to 4, covering 9 symptom dimensions. The Global Severity Index (GSI) ranges from 0 to 4; higher scores indicate greater psychological distress. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.
Time frame: At enrollment, during the standard diagnostic assessment
Emotion Dysregulation Measured by the Difficulties in Emotion Regulation Scale - Italian Short Form (DERS-IT-SF)
Emotion dysregulation assessed with the DERS-IT-SF, a self-report questionnaire rated on a 5-point Likert scale. Higher total and subscale scores indicate greater difficulties in emotion regulation. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.
Time frame: At enrollment, during the standard diagnostic assessment
Plan to share: Undecided — A decision on sharing individual participant data has not yet been made. Any future sharing of pseudonymized data would take place only in accordance with the informed consent, the EU General Data Protection Regulation (GDPR), and applicable Italian data protection law.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 12 months is below that.
Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS San Gerardo dei Tintori